Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors

被引:455
作者
Zolotukhin, S
Potter, M
Zolotukhin, I
Sakai, Y
Loiler, S
Fraites, TJ
Chiodo, VA
Phillipsberg, T
Muzyczka, N
Hauswirth, WW
Flotte, TR
Byrne, BJ
Snyder, RO
机构
[1] Univ Florida, Coll Med, Powell Gene Therapy Ctr, Gainesville, FL 32610 USA
[2] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA
[3] Univ Florida, Coll Med, Dept Pediat, Gainesville, FL 32610 USA
[4] Univ Florida, Coll Med, Dept Opthamol, Gainesville, FL 32610 USA
关键词
adeno-associated virus; gene therapy; chromatography; purification; serotype;
D O I
10.1016/S1046-2023(02)00220-7
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Recombinant adeno-associated viral (rAAV) vectors based on serotype 2 are currently being evaluated most extensively in animals and human clinical trials. rAAV vectors constructed from other AAV serotypes (scrota pes 1, 3, 4, 5 and 6) can transduce certain tissues more efficiently and with different specificity than rAAV2 vectors in animal models. Here, e describe reagents and methods for the production and purification of AAV2 inverted terminal repeat-Containing vectors pseudotyped with AAV1 or AAV5 capsids. To facilitate pseudotyping, AAV2rep/AAV1cap and AAV2rep/AAV5cap helper plasmids were constructed in an adenoviral plasmid backbone. The resultant plasmids, pXYZ1 and pXYZ5. were used to produce rAAV1 and rAAV5 vectors. respectively, by transient transfection. Since neither AAV5 nor AAV1 binds to the heparin affinity chromatography resin used to purify rAAV2 vectors, purification protocols were developed based on anion-exchange chromatography. The purified vector stocks are 99% pure with titers of 1 X 10(12) to 1 X 10(13) vector genomes/ml. (C) 2002 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:158 / 167
页数:10
相关论文
共 52 条
[41]   TARGETED INTEGRATION OF ADENOASSOCIATED VIRUS (AAV) INTO HUMAN CHROMOSOME-19 [J].
SAMULSKI, RJ ;
ZHU, X ;
XIAO, X ;
BROOK, JD ;
HOUSMAN, DE ;
EPSTEIN, N ;
HUNTER, LA .
EMBO JOURNAL, 1991, 10 (12) :3941-3950
[42]   HELPER-FREE STOCKS OF RECOMBINANT ADENO-ASSOCIATED VIRUSES - NORMAL INTEGRATION DOES NOT REQUIRE VIRAL GENE-EXPRESSION [J].
SAMULSKI, RJ ;
CHANG, LS ;
SHENK, T .
JOURNAL OF VIROLOGY, 1989, 63 (09) :3822-3828
[43]   USE OF A RECOMBINANT RETROVIRUS TO STUDY POSTIMPLANTATION CELL LINEAGE IN MOUSE EMBRYOS [J].
SANES, JR ;
RUBENSTEIN, JLR ;
NICOLAS, JF .
EMBO JOURNAL, 1986, 5 (12) :3133-3142
[44]  
Snyder R, 1996, CURRENT PROTOCOLS HU
[45]   Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions [J].
Summerford, C ;
Samulski, RJ .
JOURNAL OF VIROLOGY, 1998, 72 (02) :1438-1445
[46]   ADENOASSOCIATED VIRUS (AAV) REP PROTEINS MEDIATE COMPLEX-FORMATION BETWEEN AAV DNA AND ITS INTEGRATION SITE IN HUMAN DNA [J].
WEITZMAN, MD ;
KYOSTIO, SRM ;
KOTIN, RM ;
OWENS, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (13) :5808-5812
[47]   Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid:: Epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection [J].
Wobus, CE ;
Hügle-Dörr, B ;
Girod, A ;
Petersen, G ;
Hallek, M ;
Kleinschmidt, JA .
JOURNAL OF VIROLOGY, 2000, 74 (19) :9281-9293
[48]   Adeno-associated virus vector-mediated transgene integration into neurons and other nondividing cell targets [J].
Wu, P ;
Phillips, MI ;
Bui, J ;
Terwilliger, EF .
JOURNAL OF VIROLOGY, 1998, 72 (07) :5919-5926
[49]   Gene therapy vectors based on adeno-associated virus type 1 [J].
Xiao, WD ;
Chirmule, N ;
Berta, SC ;
McCullough, B ;
Gao, GP ;
Wilson, JM .
JOURNAL OF VIROLOGY, 1999, 73 (05) :3994-4003
[50]   Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus [J].
Xiao, X ;
Li, J ;
Samulski, RJ .
JOURNAL OF VIROLOGY, 1998, 72 (03) :2224-2232